<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860222</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2012-002-12</org_study_id>
    <nct_id>NCT01860222</nct_id>
  </id_info>
  <brief_title>Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma</brief_title>
  <official_title>A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the operative complication and short-/long-term
      therapeutic effects of percutaneous local ablative therapy (PLAT) versus surgical
      resection(SR) on small hepatocellular carcinoma(HCC) patients with clinically significant
      portal hypertension(CSPH) so as to lend clinical and theoretical basis of the therapeutic
      schemes for the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCC is a major health problem worldwide, with an estimated incidence ranging between 500,000
      and 1,000,000 new cases annually. It is the fifth most common cancer in the world and the
      third most common cause of cancer-related death,especially in East-Asia countries.SR remains
      the first therapeutic option for a cure but is suitable only for 9%—27% of patients.The
      presence of significant background cirrhosis often precludes liver resection for HCC.Even
      though these HCC patients undergo SR，the incidence of posthepatectomy liver failure(PHLF) and
      death would be high，especially to HCC patients complicating CSPH，whose corresponding risk of
      PHLF and persistent PHLF were 59.02%and 14.75%respectively in our past study. It is extremely
      urgent to search a safe and effective means in this subgroup of HCC patients.PLAT, a recently
      developed local ablative technique, has attracted the greatest interest and popularity
      because of its effectiveness and safety,with a 3-year survival rate of 62-77%,a low treatment
      complication rate of 8-9% and a low treatment mortality rate of 0-0.5%.However, there is
      still debate on whether PLAT or SR is the most suitable therapy for HCC.To our
      knowledge,there have been no study on the therapy of HCC complicating CSPH.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local tumor progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hepatocellular Carcinoma With CSPH</condition>
  <arm_group>
    <arm_group_label>SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SR</intervention_name>
    <arm_group_label>SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PLAT</intervention_name>
    <arm_group_label>PLAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 Years ＜ ge ≤ 70 Y,KPS ≥ 70

          2. A solitary HCC ≤ 5cm in diameter,or multiple HCC(≤3) ,each ≤3cm in diameter without
             evidence of radiologically definable vascular invasion or extrahepatic metastasis.
             allowing to both SR and PLAT

          3. Child-Pugh class A or B,without history of encephalopathy,ascites refractory to
             diuretics,or variceal bleeding

          4. NO previous treatment of HCC

          5. Platelet count＞40,000/mm3；prothrombin time prolongation of no more than 3 seconds

          6. Patients who can understand this trial and have signed information consent

        Exclusion Criteria:

          1. metastatic liver cancer

          2. Patients with apparent cardiac,pulmonary,cerebral and renal dysfunction,which may
             affect the treatment of HCC

        3) Patients with other diseases which may affect the treatment mentioned

        4） Patients participating in other clinical trials

        5） Patients with a medical history of other malignant tumors

        6) Pregnant and breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wu dong, MD</last_name>
      <phone>0086-021-81875532</phone>
      <email>wuyuz@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>qu shuping, doctor</last_name>
      <phone>0086-021-81875533</phone>
      <email>shupingqu33@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wu dong, MD</last_name>
      <phone>0086-021-81875532</phone>
      <email>wuyuz@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>qu shuping, doctor</last_name>
      <phone>0086-021-81875533</phone>
      <email>shupingqu33@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>wu dong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>vice president of the Eastern Hepatobiliary Surgery Hospital</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>CSPH</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>percutaneous local ablative</keyword>
  <keyword>therapy (PLAT)</keyword>
  <keyword>randomized controlled trials(RCTs)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

